-
The S&P 500 increased by 0.1% on Wednesday, May 14, 2025, driven primarily by gains in the tech sector, despite some economic worries impacting other areas.
-
Shares of Supermicrocomputer soared after the company secured a significant agreement with Saudi data center firm DataVolt.
-
Meanwhile, several life science companies addressed their operational struggles during healthcare conferences, leading to declines in their stock prices.
Mid-week trading saw mixed results among major US equity indices. Nvidia, a key player in chip manufacturing, and other tech stocks showed some recovery, but trade and economic uncertainties weighed on most other sectors.
By the end of Wednesday’s trading, the S&P 500 had gained 0.1%. The strong performance of tech stocks lifted the NASDAQ by 0.7%, while the Dow faced a slight decline of 0.2%.
Supermicro’s stocks surged by 15.7%, marking the strongest performance of the day, following their announcement of a $20 billion deal with DataVolt. The market’s focus is heightened this week as President Trump embarks on a Middle East tour. Nvidia and AMD, both partners of Supermicro, also saw their shares acquire a boost from the deal.
Enphase Energy experienced a notable increase of 5.8%, thanks to the launch of a new solar battery system in Belgium. This innovative product aims to help residents with limited roof space harness renewable energy from balconies or patios, indicating Enphase’s growing presence in Europe.
On the other hand, shares of Georgia Pacific, a containerboard producer, dropped by 4.8% after news broke of a plant closure in Cedar Springs, Georgia. In contrast, peers like Packaging Corp. of America and Smurfit Westlock saw their stocks rise.
After presenting at the BOFA Securities 2025 Healthcare Conference, Bio-Techne’s stock plummeted by 7.3%. They cited issues with order timing for diagnostic reagents and controls as deterrents to growth. The company is exploring strategies to counter potential tariff impacts by relocating manufacturing, particularly given uncertainties in government funding.
Revvity, another life sciences and diagnostics firm, also faced a setback, with a 5.9% drop in shares after the same conference. They highlighted growth in diagnostics and software but encountered tariff-related obstacles, especially concerning operations in China.
IQVIA Holdings, which provides analytics and research services, similarly experienced a 5.9% decline. At the BOFA conference, they noted that clients are delaying purchasing decisions within the current uncertain economic climate, alongside pressures on pricing within their services.
